Strategies to Limit ARIA Associated with Alzheimer Disease Treatment

Dawn Brooks, PhD, Global Development Leader, Eli Lilly and Company, and John Sims, MD, Senior Medical Director, Eli Lilly and Company, discuss new findings on baseline characteristics about amyloid-related imaging abnormalities (ARIA) in people with Alzheimer disease treated with donanemab.
Learn more about your ad choices. Visit megaphone.fm/adchoices